BioCanada

Found 34,530 articles

• Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases

  6/7/2023

  New grant from the Bill & Melinda Gates Foundation supports the development of genetic therapies for infectious diseases.

• Ceapro Announces Results of 2023 Shareholders’ Meeting

  6/7/2023

  Ceapro Inc. announced that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 6, 2023 as per the following results.

• Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 7, 2023

  6/7/2023

  Fusion Pharmaceuticals Inc. today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,000 shares of its common stock to two employees outside Fusion's 2020 Stock Option and Incentive Plan.

• Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer

  6/7/2023

  Lobe Sciences Ltd. today announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately.

• Therma Bright's Investment Partner Inretio Announces Successful Completion of GLP Study for PREVA(TM) Thrombectomy Device

  6/7/2023

  Both Companies Anticipates Approval to Launch of Human Clinical Trials

• Nirvana Life Sciences Inc. Announces the Acquisition of Licensed Distributor of a Patented, WHO Approved, Herbal Treatment for Opiate Addiction

  6/7/2023

  Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines,

• Justera Health Expands Presence with New IV Therapy Lounge in Vancouver

  6/7/2023

  Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) ("Justera" or the "Company") is pleased to announce the launch of its intravenous (IV) therapy lounge in Vancouver, now open to the public.

• Satellos Bioscience Announces Appointment of Chief Medical Officer

  6/7/2023

  Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023

• Alpha Cognition Receives Army Medical Research Grant for Study on Mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology

  6/7/2023

  Alpha Cognition Inc. is pleased to announce the that it has been awarded a $750,000 grant from the Army Medical Research and Material Command (AMRMC) for a pre-clinical study on the use of ALPHA-1062 Intranasal (IN) to reduce blast mTBI induced functional deficit and brain abnormalities.

• Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec

  6/6/2023

  Thryv Therapeutics Inc. announced the closing of a USD $5,000,0000 convertible note investment by Investissement Québec.

• Achieve Life Sciences Announces Participation at Upcoming June 2023 Investor Conferences

  6/6/2023

  Achieve Life Sciences, Inc. announced that John Bencich, CEO of Achieve, will be presenting at the LD Micro Invitational XIII in Los Angeles and the Maxim Virtual Healthcare Conference.

• BIOREM order backlog exceeds $50 million on strength of $11-million in new orders

  6/6/2023

  BIOREM Inc. announced $10.6 million of new orders for air emission abatement projects in North America.

• IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

  6/6/2023

  ImmunoPrecise Antibodies Ltd. introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and its subsidiary, BioStrand®.

• Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023

  6/6/2023

  Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results in advanced gastric and biliary tract cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2023

  6/6/2023

  Avivagen Inc. has announced its unaudited financial results for the Second quarter of 2023.

• Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

  6/6/2023

  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), an Israel-based dermatology company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, today announced the signing of exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market.

• ESSA Pharma Appoints Lauren Merendino to its Board of Directors

  6/6/2023

  ESSA Pharma Inc. today announced the appointment of Lauren Merendino , M.B.A., to its Board of Directors.

• Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

  6/6/2023

  Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors.

• Theralase(R) Announces Appointment of New Independent Director

  6/6/2023

  Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.

• Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000

  6/6/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has increased the size of its previously announced non-brokered private placement ("Offering") from up to $2 million in proceeds to $2,766,375 and 11,065,500 units (the "Units" or each a "Unit").